TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Inmune Bio ( (INMB) ) has issued an update.
On November 18, 2025, INmune Bio held a virtual special meeting of stockholders where the Option Repricing Proposal was approved. The company also announced its participation in the 18th Clinical Trials on Alzheimer’s Disease conference in December 2025, where it will present results from its Phase 2 MINDFuL trial and validation of the Early Mild Alzheimer’s Cognitive Composite.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting immunology and inflammation. The company has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, CORDStrom™, and INKmune®, which are aimed at addressing various diseases, including cancer and recessive dystrophic epidermolysis bullosa.
Average Trading Volume: 535,867
Technical Sentiment Signal: Sell
Current Market Cap: $37.75M
See more data about INMB stock on TipRanks’ Stock Analysis page.